Stock Analysis, Dividends, Split History

PTN / Palatin Technologies, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.03
Volume542,800.00
Market Cap ($M)192.72
Enterprise Value ($M)170.44
Book Value ($M)26.96
Book Value / Share0.13
Price / Book7.72
NCAV ($M)26.46
NCAV / Share0.13
Price / NCAV7.86
Share Statistics
Preferred Stock Shares Outstanding 4,030
Common Stock Shares Outstanding 200,554,205
Common Shares Outstanding 202,048,804
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.90
Return on Assets (ROA)0.43
Return on Equity (ROE)-4.78
Balance Sheet (mrq) ($M)
Assets39.02
Liabilities12.05
Quick Ration/a
Current Ratio3.58
Income Statement (mra) ($M)
Revenues67,134,758.00
Revenue From Grants0.00
Operating Income25.93
Net Income24.70
Earnings Per Share Basic0.12
Earnings Per Share Diluted0.12
Cash Flow Statement (mra) ($M)
Cash From Operations1.70
Cash from Investing0.23
Cash from Financing0.23
Identifiers and Descriptors
CUSIP696077403
Central Index Key (CIK)911216

Split History

Stock splits are used by Palatin Technologies, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
PTN : Palatin Technologies Stock Analysis and Research Report

2017-10-26 - Asif

Palatin Technologie is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (“HSDD”), which is a type of female sexual dysfunction (“FSD”), defined as low desire with associated distress. In addition, Palatin has drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The following drug development programs are actively under development: Bremelanotide, an as-needed subcutaneous injectable product for the treatment of HSDD in premenopausal women. Bremelanotide is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulat...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2018 Results - Earnings Call Transcript

2018-09-13 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Fourth Quarter and Fiscal Year End 2018 Operating Results Conference Call. As a reminder, this conference is being recorded. (32-0)

AMAG Pharmaceuticals: A Well-Positioned Player In The Pharmaceutical Space

2018-08-27 seekingalpha
Bremelanotide - AMAG's new product - withholds blockbuster potential to fulfill women's need in a billion-dollar market. (32-6)

The Women’s Libido Pill Is Back, and So Is the Controversy - Bloomberg

2018-06-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (76-11)

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors. (299-6)

Palatin shares surge 9% premarket after FDA accepts for review treatment for HSDD - MarketWatch

2018-06-04 marketwatch
Palatin Technologies Inc. shares PTN, +7.21% surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. AMAG, +0.61% Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. (59-0)

CUSIP: 696077403